Ainos, Inc.

Item 1.01 Entry into a Material Definitive Agreement On September 24, 2026 (the “Effective Date”), Ainos, Inc. (the “Company”) entered into a Global Exclusive License Agreement (the “License Agreement”) with BioPhoenix Co., Ltd., a company organized under the laws of the Republic of China (Taiwan) (“BioPhoenix”). The License Agreement covers the Company’s VELDONA® low-dose oral interferon alpha technology platform. Under the License Agreement, the Company granted BioPhoenix an exclusive, worldwide, irrevocable, transferable and sublicensable license under certain of the Company’s intellectual property and related assets. The license allows BioPhoenix to research, develop, manufacture, have manufactured, use, import, export, offer for sale, sell, commercialize and otherwise exploit VELDONA® for Sjögren’s Disease and Thrombocytopenia (the “Licensed Indications”). The licensed territory covers all countries and territories worldwide. During the term and for 10 years after it ends, the Company may not compete with the Licensed Indications anywhere in the world. The Company also granted BioPhoenix a right of first refusal and a call option to license certain additional VELDONA® indications that have progressed to Phase 2 clinical trials. BioPhoenix further has an option to license other non-licensed VELDONA® indications under separate written agreements. In consideration for the license, BioPhoenix will pay the Company an upfront license fee of $600,000. The upfront fee is due after BioPhoenix receives the complete data package and written confirmation that technology transfer is complete. BioPhoenix will also pay the Company a one-time fee when it grants its first sublicense to a third party. If BioPhoenix licenses all of the additional VELDONA® indications available under the License Agreement, the total license fees payable to the Company, including the upfront license fee and the first sublicense fee, would be approximately $10.0 million. In addition, the Company will receive twenty-five percent (25%) of BioPhoenix’s net sublicensing revenue for the Licensed Indications. The License Agreement continues on an indication-by-indication and country-by-country basis until the later of (a) the expiration of the last-to-expire patent covering the applicable Licensed Indication or (b) 20 years after the Effective Date, unless terminated earlier. Either party may terminate the License Agreement for the other party’s uncured material breach or insolvency. The License Agreement contains customary representations, warranties, covenants, indemnification obligations and confidentiality provisions. The foregoing description of the License Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the License Agreement, a copy of which is filed with this current report on Form 8-K as Exhibit 10.1 and is hereby incorporated herein by reference.

Item 7.01 Regulation FD Disclosure On September 28, 2026, the Company announced the execution of the License Agreement with BioPhoenix. A copy of the press release issued by the Company in this connection is furnished herewith as Exhibit 99.1. The information furnished with this Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act.